Physician profile
Mark D Chazen
NPI 1518931989
$3,750.24
in general payments reported to CMS, 2019-2025
23 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $353 · 2021: $565 · 2022: $935 · 2023: $623 · 2024: $428 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,314.04 | 2019-2024 | Myrbetriq |
| Abbvie INC. | $1,034.32 | 2019-2025 | Lupron Depot, Botox |
| Allergan, INC. | $314.42 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $208.96 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $161.41 | 2021-2022 | |
| Boston Scientific Corporation | $127.13 | 2022 | |
| Pfizer INC. | $95.77 | 2019-2024 | |
| Medtronic USA, INC. | $80.36 | 2019-2020 | |
| Janssen Biotech, INC. | $61.74 | 2019-2022 | |
| Medtronic, INC. | $44.02 | 2021 | |
| Endo Pharmaceuticals INC. | $35.99 | 2023 | Xiaflex, Aveed, Edex |
| Teleflex LLC | $31.18 | 2024-2025 | Barrigel, Urolift |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| Axonics, INC. | $27.75 | 2021 | |
| Ferring Pharmaceuticals INC. | $25.39 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.19 | 2025 | Rivfloza |
| Tolmar Pharmaceuticals, INC. | $23.61 | 2021 | |
| Accord Healthcare, INC. | $22.13 | 2024 | |
| Calyxo, INC. | $20.11 | 2024 | Cvac Aspiration System |
| Tolmar, INC. | $19.77 | 2024 | |
| Myovant Sciences INC. | $17.02 | 2022 | |
| Olympus America INC. | $15.78 | 2023 | Itind System |
| Neotract INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chazen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.